Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short versus long hydration during cisplatin in head and neck cancer
2020-003890-23Phase 4Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cisplatin in head and neck cancer (HNC) (2 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: Incidence of cisplatin-induced nephrotoxicity. Started Feb 2021; status: active.
02
Drugs
cisplatin
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on 2020-003890-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003890-23.